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Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
P-3
The UK plasma based Molecular profiling of Advanced breast cancer
to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple
parallel-cohort, phase IIa platform trial aiming to provide proof of
principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
Sarah Kernaghan1, Laura Moretti1, Lucy Kilburn1, Katie Wilkinson1, Claire
Snowdon1, James Morden1, Iain Macpherson2, Andrew Wardley3,
Rebecca Roylance4, Richard Baird5, Alistair Ring6, Nicholas Turner7,
Judith M Bliss1, on behalf of the plasmaMATCH Trial Management
Group
1Clinical Trials and Statistics Unit at The Institute of Cancer Research
(ICR-CTSU), United Kingdom; 2The Beatson West of Scotland Cancer
Centre, Glasgow, United Kingdom; 3The Christie NHS Foundation Trust,
Manchester, United Kingdom; 4University College London Hospitals NHS
Foundation Trust, London, United Kingdom; 5Cambridge University
Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 6The
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 7The
Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust, London, United Kingdom
Trials 2019, 20(Suppl 1):P-3
Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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digital tool, with examples, will inform the NIHR research community
about choices and help them identify potential tools to support re-
cruitment and retention.
P-245
Lessons learnt from a multi-centre Type 3 surgical trial
Katie Biggs1, Daniel Hind1, Mike Bradburn1, Lizzie Swaby1, Steven Brown2
1University Of Sheffield, Sheffield, UK; 2Sheffield Teaching Hospitals NHS
Trust, Sheffield, UK
Trials 2019, 20(Suppl 1):P-245
Background: Pragmatic randomised controlled trials are increasingly
being used to evaluate surgical interventions, although they present
particular difficulties in regard to recruitment and retention.
Methods
This paper details the procedures and processes related to imple-
mentation of a multi-centre pragmatic surgical randomised con-
trolled trial.
Results: Forecasting consent rates based on previous similar trials en-
sured that the recruitment window was of adequate length. Ad-
equate resource was available for study procedures at multiple
clinics in each hospital due to micro-costing of study activities with
research partners ensure. A video was produced targeting recruiting
staff, which aimed to help recruiters explain the trial, randomisation
and equipoise, based on methodological work and experiences from
another study. Post-randomisation delays in delivering surgery to
one study arm were investigated by assessing the outcomes at the
time of randomisation and the day of surgery which provided confi-
dence in the baseline measure. Real-time monitoring of participant
drop-out due to delays in surgery meant we were able to extend the
recruitment window in a timely fashion. Triangulation of data sources
ensured adequate numbers of participants provided primary out-
come data.
Discussion: This paper provides a range of evidence- and
experience-based approaches which resulted in meeting our study’s
objectives and these lessons may be transferable.
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Challenges in the design, planning and implementation of trials
evaluating group interventions
Katie Biggs1, Daniel Hind1, Rebecca Gossage-Worrall1, Kirsty Sprange2,
David White1, Jessica Wright1, Robin Chatters1, Katherine Berry3, Diana
Papaioannou1, Mike Bradburn1, Stephen J Walters1, Cindy L Cooper1
1ScHARR, University of Sheffield, Sheffield, UK; 2NCTU, University of
Nottingham, Nottingham, UK; 3School of health Sciences, University of
Manchester, Manchester, UK
Trials 2019, 20(Suppl 1):P-246
Background: Evaluating group interventions in randomised con-
trolled trials (RCTs) presents a set of practical problems which may
not be immediately obvious and are not present in RCTs of one-to-
one interventions.
Methods
Case-based approach summarising Sheffield clinical trial unit’s experi-
ence in the design and implementation of group interventions across
five randomised controlled trials.
Results: Median recruitment across the five trials was 5.8 (range 2.1-
16.0) participants per site per month. Group intervention trials can in-
volve a delay in the start of treatment whilst waiting for sufficient
numbers to start a group. There was no evidence in our trials that
the timing of consent, relative to randomisation, affected post-
randomisation attrition, but attrition was a concern for all trial teams.
Group facilitator attrition was common in studies where facilitators
were employed by the health-system rather than the by the grant
holder, and lead to the early closure of one trial. Solutions to this in-
cluded training ‘back-up’ and new facilitators. Trials specified that
participants had to attend a median of 62.5% (range 16.7% to 80%)
of sessions, in order to receive a ‘therapeutic dose’; a median of
75.0% (range 34.6% to 97.8%) received a therapeutic dose. Across
the five trials, 66.4% of all sessions ran with fewer than the numbers
pre-specified as ideal. A variety of methods were used to assess the
fidelity of group interventions across the five trials.
Discussion: Investigators should expect delays / difficulties in recruit-
ing groups of the optimal size, plan for both facilitator and partici-
pant attrition and consider how group attendance and group size
affects treatment fidelity.
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Delivering site set-up training to groups of sites versus
individually: a randomised study within a trial
Eleanor Mitchell1, Alan Montgomery1, Garry Meakin1, Rachel Haines1,
Reuben Ogollah1, Chris Partlett1, Kate Walker1, Jon Dorling2, Shalini
Ojha3, on behalf of the FEED1 Collaborative Group
1Nottingham Clinical Trials Unit, University of Nottingham, Nottingham,
United Kingdom; 2Dalhousie University, Halifax, Canada; 3Division of
Graduate Entry Medicine & Medical Sciences, University of Nottingham,
Nottingham, United Kingdom
Trials 2019, 20(Suppl 1):P-247
Introduction: Site initiation visits (SIVs) are conducted to deliver
training to sites before opening them to recruitment, though this
can be burdensome during the time-intensive trial set-up period.
There is little evidence about the best way to deliver training for sites
to perform well. Evaluating methods of training was the highest pri-
ority identified at a workshop exploring recruitment and retention of
participants to trials. Two systematic reviews investigating training in
clinical trials showed a variety of different training methods and
more research is needed to determine what kind of training and sup-
port can improve recruitment. A small retrospective study showed
that, whilst face-to-face training (either at SIV or group training ses-
sion) was associated with better recruitment than remote training
(i.e. telephone or DVD), no difference was seen between the two
types of face-to-face training.
Our objective is to compare group-based training during the trial
set-up period versus visiting the site to conduct a SIV to investigate
the impact of the training method upon key site performance met-
rics. We will embed a SWAT into the FEED1 trial, funded by the NIHR
HTA programme.
Methods: Once selected, sites will be randomised in batches to re-
ceiving their site-initiation training during a SIV or group-based train-
ing by attending a collaborators’ meeting. To allow for non-
availability of site staff, two meetings will be held. Outcomes will in-
clude recruitment and retention, data quality and protocol compli-
ance (defined as core site performance metrics) and associated costs
of each training method.
Timing of potential results: Clinical trial and SWAT results will be
available in Q1 of 2023.
Potential relevance and impact: If the intervention is shown to be
effective, there could be significant benefits to funders and trial
teams, in particular reducing the length of time it takes to set-up a
trial and open all sites.
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Making a challenging trial possible: Lessons from the Emergency
Department led EcLiPSE trial
Kerry Woolfall1, Louise Roper1, Mark. D Lyttle4, Carrol Gamble5, Amy
Humphreys5, Shrouk Messahel3, Elizabeth Lee3, Joanne Noblet3, Helen
Hickey5, Naomi E.A Rainford5, Anand Iyer2, Richard Appleton2
1University of Liverpool, United Kingdom; 2Neurology Department Alder
Hey Children’s NHS Foundation Trust, United Kingdom; 3Emergency
Department, Alder Hey Children’s NHS Foundation Trust, United
Kingdom; 4Emergency Department, Bristol Royal Hospital for Children,
United Kingdom; 5University of Liverpool, Clinical Trials Research Centre
(CTRC), United Kingdom
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